CTMX CytomX Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1501989 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.69M | $1.42M | $10.26M | $663,000 | $5.96M | $18.66M | $50.92M | $38.09M |
| R&D expense | $16.48M | $17.60M | $19.24M | $21.23M | $15.30M | $13.32M | $18.87M | $14.79M |
| SG&A expense | $8.71M | $7.60M | $10.69M | $7.36M | $6.43M | $6.62M | $9.43M | $5.62M |
| Operating income | -$23.50M | -$23.78M | -$19.67M | -$27.93M | -$15.77M | -$1.29M | $22.62M | $17.68M |
| Pretax income | -$19.94M | -$20.61M | -$18.19M | -$26.46M | -$14.17M | -$91,000 | $23.59M | $18.94M |
| Income tax | $61,000 | $60,000 | $59,000 | $54,000 | $58,000 | $63,000 | $62,000 | $62,000 |
| Net income | -$20.00M | -$20.67M | -$18.25M | -$26.51M | -$14.23M | -$154,000 | $23.52M | $18.88M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | 219.11M | 218.94M | 177.27M | — | 165.00M | 129.08M | 87.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $33.96M | $17.22M | $28.83M | $12.67M | $34.19M | $49.04M | $47.60M | $38.05M |
| Short-term investments | $314.02M | $313.06M | $317.88M | $124.39M | $109.44M | $109.05M | $32.28M | $62.57M |
| Receivables | $501,000 | $37.49M | $646,000 | $2.01M | $1.63M | $1.87M | $1.96M | $3.10M |
| Current assets | $356.05M | $373.15M | $353.10M | $143.92M | $149.22M | $164.62M | $86.63M | $107.31M |
| PP&E, net | $2.52M | $1.08M | $1.09M | $1.30M | $1.72M | $1.95M | $2.23M | $2.47M |
| Goodwill | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 |
| Total assets | $364.68M | $381.23M | $359.36M | $151.57M | $158.25M | $175.06M | $98.50M | $120.53M |
| Current liabilities | $45.53M | $39.86M | $34.02M | $46.62M | $41.03M | $39.22M | $50.20M | $85.77M |
| Total liabilities | $79.79M | $79.16M | $39.41M | $52.56M | $50.87M | $55.15M | $73.45M | $120.99M |
| Shareholders' equity | $284.89M | $302.07M | $319.94M | $99.01M | $107.39M | $119.91M | $25.05M | -$456,000 |
| Shares outstanding | — | — | — | 170.19M | — | — | — | 80.10M |
| Cash flow statement | ||||||||
| Operating cash flow | $16.65M | -$18.07M | -$25.55M | -$23.24M | -$15.55M | -$15.75M | -$21.04M | -$19.91M |
| Capital expenditure | $589,000 | $0 | $0 | $201,000 | -$127,000 | $27,000 | $119,000 | $80,000 |
| Free cash flow | $16.06M | -$18.07M | -$25.55M | -$23.44M | -$15.42M | -$15.78M | -$21.16M | -$19.99M |
| Investing cash flow | -$3,000 | $5.95M | -$192.78M | -$14.42M | $439,000 | -$76.36M | $30.60M | $15.13M |
| Financing cash flow | $94,000 | $511,000 | $234.49M | $16.64M | $253,000 | $93.55M | $0 | $2.25M |
| Stock-based compensation | $2.84M | $2.58M | $4.71M | $1.48M | $1.38M | $1.43M | $2.01M | $1.88M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.